PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma

• Michael B. Atkins,
• Suthee Rapisuwon,
• Arash Radfar,
• Kellie Gardner,
• Neil J. Shah,
• Geoffrey T. Gibney,
• Jacob Zaemes,
• Shelly Shand,
• David Swoboda,
• Vesna Petronic-Rosic,
• Michael J. Reilly,
• Waddah B. Al-Refaie

Affiliations

Michael B. Atkins

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Suthee Rapisuwon

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Arash Radfar

Inform Diagnostics, Irving, Texas, USA

Kellie Gardner

MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Neil J. Shah

Memorial Sloan Kettering Cancer Center, New York, New York, USA

Geoffrey T. Gibney

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Jacob Zaemes

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Shelly Shand

Charleston Oncology, Charleston, South Carolina, USA

David Swoboda

Moffitt Cancer Center, Tampa, Florida, USA

Vesna Petronic-Rosic

Georgetown University Medical Center, Washington, District of Columbia, USA

Michael J. Reilly

MedStar Georgetown University Hospital, Washington, District of Columbia, USA

Waddah B. Al-Refaie

MedStar Georgetown University Hospital, Washington, District of Columbia, USA